Moteur de recherche d’entreprises européennes
Financement de l’UE (15 M €) : Solutions photoniques à l’échelle pilote pour le développement accéléré de dispositifs médicaux Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Solutions photoniques à l’échelle pilote pour le développement accéléré de dispositifs médicaux
Photonics technologies have become a key enabler in the realization of modern medical devices with applications ranging from diagnostics to surgical tools and therapeutics. Characteristic nature of both photonics and application fields is high diversity. Consequently, the more widespread use of photonics technologies in scattered ecosystems presents major challenges for both end-user companies and manufacturers. In conjunction with highly regulated validation and production, the timespan from the concept phase to product launch takes years. Addressing these challenges, MedPhab will serve as Europe’s first Pilot Line dedicated to manufacturing, testing, validation and up-scaling of new photonics technologies for medical diagnostics enabling accelerated product launch with reduced R&D costs. MedPhab will bring the high-quality infrastructure and extensive know-how within easy reach of the SME’s and other European Industry. Globally unique feature of MedPhab is its operation in medical domain setting requirements to meet regulations. The competitive differentiation is the seamless operation between ISO13485 certified companies and RTOs when single-entry point can serve SMEs operating at different TRLs. Professional customer interface will be operated by staff with extensive experience in the field medical devices. The technology readiness and MedPhab operation process will be validated by: 1) Use Case Validation program, upscaling and demonstrating performance of 5 innovative medical diagnostics products; 2) Demo Case Open Calls program enabling early adoption of the technologies by external user, demonstrating the pilot line services and validating the open access business model.
| Amires s.r.o. | 93 275 € |
| Amires The Business Innovation Management Institute ZU | 169 225 € |
| Antelope DX | 26 734 € |
| CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT | 1 538 492 € |
| European Photonics Industry Consortium | 407 500 € |
| Genspeed Biotech GmbH | 192 063 € |
| III-V LAB | 563 467 € |
| Interuniversitair Micro-Electronica Centrum | 1 545 421 € |
| Jabil Circuit Austria GmbH | 554 179 € |
| Joanneum Research Forschungsgesellschaft mbH | 1 328 896 € |
| MACULASER Oy | 162 225 € |
| Meep | 220 516 € |
| Nypro Ltd. | 116 250 € |
| PHILIPS ELECTRONICS NEDERLAND B.V. | 1 729 726 € |
| POLAR ELECTRO Oy | 841 225 € |
| Radisens Diagnostics Ltd. | 280 046 € |
| SCREENTEC Oy | 183 890 € |
| STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS | 302 250 € |
| Stryker European Operations Ltd. | 442 135 € |
| TEKNOLOGIAN TUTKIMUSKESKUS VTT Oy | 2 319 983 € |
| University College Cork - National University of Ireland, Cork | 1 870 323 € |
| Viennalab Diagnostics GmbH | 107 625 € |
https://cordis.europa.eu/project/id/871345
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
